NCT05478772View on ClinicalTrials.gov

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

August 6, 2022

Study Completion Date

August 12, 2022

Conditions
Health Volunteers
Interventions
DRUG

CTP-543

12 mg on Day 1 and Day 7

DRUG

Fluconazole

200 mg once daily on Days 3 through to Day 8

Trial Locations (1)

33014

Clinical Pharmacology of Miami, LLC, Miami

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY